Genome Sequencing

Sequencing a person’s genome can identify susceptibility to various diseases, aid in early disease diagnosis, and enable precision medicine - personalization of therapy based on individual specific genomic biomarkers.

INanoBio is developing an advanced 3D nanopore – transistor device for sequencing the whole human genome with high accuracy, at one-tenth the current cost and time. Based on CMOS semiconductor nanotechnology, it will be over 100 times faster than protein nanopore based sequencers.

INanoBio’s sequencer will enable sequencing genomes of whole populations across the world.

Cancer Diagnostics

Detecting diseases in early stages dramatically improves therapeutic outcomes. In Cancer, average 5 year survival rate is close to 90% when diagnosed at stage 1, and stands at less than 25% when diagnosed at stage 4. In contrast, cost of therapy when diagnosed post metastasis is approximately 2.5 times that when diagnosed at early stages.

INanoBio is developing advanced nano-biotechnology tools that enable discovering of disease specific molecular biomarkers and detecting them in blood with ultra-high sensitivity. We are developing simple blood tests to detect cancers early, obviating the need for biopsy.

Press

INanoBio Expands Board

Dr. Abhay Sanan and JP Million join INanoBio Board of Directors as part of 2018 Series […]

NIH SBIR GRANT

INanoBio awarded $0.7 M grant by National Institute of Health (NIH) to develop an advanced automated […]

IEEE VLSI TSA Keynote

INanoBio CEO Bharath Takulapalli to Keynote IEEE VLSI TSA conference in Taiwan.

Read more

Career

Grants Program Manager

INanoBio is developing pioneering technologies at the confluence of nanotechnology, systems biology and machine learning, to […]

Post doctoral Fellow: Molecular Biology

INanoBio has an opening for postdoctoral researcher with strong experimental background in molecular biology, biochemistry and […]

Research Scientist

INanoBio is seeking a Research Scientist to join our fast-paced multi-disciplinary molecular diagnostics & devices team […]

Read more

Company

INanoBio’s mission is to develop high-accuracy early stage disease diagnostics that will enable early personalized therapeutic intervention preempting full development of diseases. We believe up to 90% of current diseases can be detected early and simply preempted, to usher in a relatively healthy future in two to three decades.

uparrow